MB Therapeutics took part this week in two major events where pharmaceutical innovation was at the heart of the discussions: the 3D PharmaPrint Healthcare Symposium in Rotterdam and the A3P Product Life Cycle in Lyon. These events offered an opportunity to share ideas, explore the latest innovations, and discuss the upcoming challenges in the pharmaceutical industry.

3D PharmaPrint Healthcare Symposium – Rotterdam

The 3D PharmaPrint Healthcare Symposium, organized in Rotterdam, brought together industry experts to discuss the impact of pharmaceutical 3D printing on the healthcare sector. This technology offers innovative perspectives, particularly for drug personalization and the manufacture of tailor-made dosage forms.

At MB Therapeutics, we firmly believe that 3D printing is the key to transforming how drugs are designed and manufactured. Thanks to this technology, we can create treatments tailored to each patient, based on their specific needs, enabling more precise and effective medicine. This symposium confirmed the central role of 3D printing in the future of pharmacy.

A3P Product Life Cycle – Lyon 

In Lyon, the A3P Product Life Cycle offered a privileged discussion space for pharma professionals. The event highlighted key topics for the future of the industry, such as control strategy, manufacturing process management, and QbD (Quality by Design), an essential guide for optimizing pharmaceutical processes.

As a member of the GIC (Common Interest Group) of the A3P, Damien Stefanelli, COO of MB Therapeutics, was able to share his expertise on these crucial issues. Active participation in these strategic discussions allows MB Therapeutics to remain at the forefront of regulatory developments and to ensure that our personalized medicine manufacturing solutions comply with the strictest standards.

This event also highlighted the importance of process control in the pharmaceutical industry to guarantee the quality, safety, and efficacy of treatments. 

MB Therapeutics: At the heart of pharmaceutical innovation

These meetings reinforce our commitment to providing innovative and efficient solutions for the pharmaceutical industry of tomorrow. Thanks to our expertise and vision, MB Therapeutics is ready to play a major role in this transformation.